Biotie Therapies Ltd., a biopharmaceutical company, primarily focuses on developing and selling therapeutics for central nervous system disorders in Finland and the United States. The company offers Selincro (nalmefene), a dual-acting opioid system modulator that reduces alcohol consumption in alcohol dependent individuals; and Tozadenant (SYN115), an oral, potent and selective adenosine A2a receptor antagonist, which is in Phase III clinical study for the treatment of Parkinson’s disease. It also provides SYN120, an oral, potent, dual antagonist of the 5-HT6 and 5-HT2A receptors that has been completed single and multiple ascending dose Phase I clinical studies and a Phase I positron emission tomography imaging study to determine therapeutic dose for subsequent Phase II studies; and BTT1023, a human monoclonal antibody that binds to vascular adhesion protein 1, which is in Phase II clinical trial received orphan drug designation for the treatment of primary sclerosing cholangitis. Biotie Therapies Ltd. was formerly known as Biotie Therapies Corp. The company is headquartered in Turku, Finland. As of April 18, 2016, Biotie Therapies Ltd. operates as a subsidiary of Acorda Therapeutics, Inc.